21 recruiting, 7 not yet recruiting, 5 active not recruiting, 5 completed. 23 Phase 1, 20 Phase 2, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Mantle Cell Lymphoma (MCL): new trials by email Literature Review of Mantle Cell Lymphoma (MCL) trials Research Report on Mantle Cell Lymphoma (MCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma TT-01488 Tablets, Rituximab, Immunomodulatory Agent - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | TransThera Sciences (Nanjing), Inc. | 188 | 2026-10-10 | 2026-10-02 |
| This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL) | Not applicable | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2026-09-01 | 2026-02-17 |
| Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Miltenyi Biomedicine GmbH | 52 | 2026-09-01 | 2026-05-06 |
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) Orelabrutinib, Obinutuzumab, Venetoclax - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 39 | 2026-07-15 | 2026-07-22 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy Lisaftoclax, Pirtobrutinib - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 45 | 2026-06-30 | 2026-07-06 |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma LTZ-301 - Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | LTZ Therapeutics, Inc. | 42 | 2026-01-29 | 2026-07-24 |
| ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial ZSDT regimen - Mantle Cell Lymphoma (MCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 30 | 2025-12-31 | 2025-12-04 |
| Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma Pirtobrutinib and rituximab - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 50 | 2025-09-30 | 2025-12-16 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 25 | 2025-09-10 | 2026-07-28 |
| Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma Pomalidomide, Orelabrutinib, Zuberitamab - Mantle Cell Lymphoma (MCL), POZ | Not applicable | Recruiting | Peking University Third Hospital | 34 | 2025-08-01 | 2025-12-02 |
| JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma JWCAR239, Fludarabine, Cyclophosphamide - B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma | Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2025-07-01 | 2025-06-17 |
| Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment Orelabrutinib, Rituximab (R), BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 45 | 2025-07-01 | 2025-09-30 |
| Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma Acalabrutinib, Rituximab - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 50 | 2025-04-14 | 2025-06-03 |
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies EXS73565 - Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 85 | 2025-03-31 | 2026-08-13 |
| A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting Lisocabtagene maraleucel - Mantle Cell Lymphoma (MCL) | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 300 | 2025-02-04 | 2025-02-24 | |
| Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment Orelabrutinib, Bendamustine, Rituximab - Mantle Cell Lymphoma (MCL) | Phase 3 | Recruiting | Ruijin Hospital | 78 | 2024-07-10 | 2024-07-11 |
Showing 20 of 48. Sign in to see all of them.
Lymphoma, Mantle-Cell (48) · Lymphoma, Follicular (21) · Lymphoma, Large B-Cell, Diffuse (20) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma (8) · Lymphoma, B-Cell (8) · Lymphoma, Non-Hodgkin (7) · Waldenstrom Macroglobulinemia (7) · Recurrence (6) · Burkitt Lymphoma (5) · Hematologic Neoplasms (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Hodgkin Disease (2) · Leukemia, Myeloid, Acute (2)
Hemic and Lymphatic Diseases (48) · Immune System Diseases (48) · Immunoproliferative Disorders (48) · Lymphatic Diseases (48) · Lymphoproliferative Disorders (48) · Neoplasms by Histologic Type (48) · Neoplasms (47) · Lymphoma, Non-Hodgkin (41) · Lymphoma (40) · Disease Attributes (19) · Lymphoma, B-Cell (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Hematologic Diseases (18) · Leukemia, Lymphoid (18)
Rituximab (8) · venetoclax (6) · acalabrutinib (5) · orelabrutinib (5) · Cyclophosphamide (4) · fludarabine (3) · Bendamustine Hydrochloride (2) · Lisaftoclax (2) · ibrutinib (2) · pirtobrutinib (2) · zanubrutinib (2) · Adjuvants, Immunologic (1) · CF regimen (1) · Carmustine (1) · Cytarabine (1)
Ruijin Hospital (4) · Acerta Pharma BV (3) · GUSTAVO SALGUERO (2) · Guangzhou Lupeng Pharmaceutical Company LTD. (2) · MEI Pharma, Inc. (2) · Miltenyi Biomedicine GmbH (2) · Nurix Therapeutics, Inc. (2) · Peking University Third Hospital (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Sun Yat-sen University (2) · AbbVie (1) · Amgen (1) · AstraZeneca (1) · Calibr, a division of Scripps Research (1) · Exelixis (1)
China (18) · United States (18) · Poland (7) · United Kingdom (6) · Spain (5) · Canada (4) · France (4) · Italy (4) · Australia (3) · Germany (3) · Switzerland (3) · Belgium (2) · Netherlands (2) · Brazil (1) · Czechia (1)
Alain Monnereau, MD (1) · Connie Batlevi, MD, PhD (1) · Emilian Snarski (1) · Gustavo Salguero, MD PhD MBA (1) · Hongmei Jing, Professor (1) · Ingo Tamm, PD Dr. (1) · Jens Kisro, Dr. (1)
PMID 36375120, PMID 29241979, PMID 32175617, PMID 33653294, PMID 34515338, PMID 34531588, PMID 35597752, PMID 35835137, PMID 37874913, PMID 38143760, PMID 38781315, PMID 39705540, PMID 40163793, PMID 40809193, PMID 41633358, PMID 42212152
2023 (4), 2014 (1), U24HL138660 (1)